$16 million in seed investment was secured by OverT Bio, a data-driven startup located in New York City that aims to allow the curative potential of cell therapy in solid tumors.
Investors
- Fusion Fund
- OMX Ventures
- Alexandria Venture Investments
- Gaingels
- Civilization Ventures
- Hawktail
- Cancer Research Institute
- ARTIS Ventures
- Wing VC
Use of funds
The money will be used by the business to develop discovery platforms that target the main obstacles to cell therapy in an effort to develop long-lasting and effective therapies for advanced solid malignancies.
Its central platform looks up every gene in the genome to find the most advantageous genetic alterations that give immune cells new abilities. The business has also developed a high-throughput method to find novel, safe, and effective receptors and targets.
To identify novel receptors and targets that are applicable to the entire human population, OverT leverages the immune response seen by cancer patients. The complete human genome is searched by the researchers in an effort to develop novel approaches for enhancing the durability and anti-tumor efficacy of cell treatments.
About OverT Bio
Dr. Mat Legut and Neville Sanjana founded OverT Bio in 2022 with the goal of addressing significant unmet medical needs in solid tumors. The company has created platforms for synthetic biology, single-cell multiomic analysis, and parallel genomic screening that integrate big data analysis techniques with cell engineering technologies.
